(**Reflo**Dx Better Diagnostics, Better Lives

One Line Summary:

Our patented low-risk ultrasound technology is now the new gold standard for diagnosing reflux noninvasively and at a lower cost, for the 65 million Americans who suffer from it.

Business Summary:

RefloDX will use investor funds to obtain the human and material resources to quickly develop and manufacture the SondefluxTM reflux detector, bring it to market, and scale up to meet or exceed market sales projections.

Management:

Rudy Wilcox (CEO) has 11 years industry experience, with background in electrical, computer, and biomedical engineering, medical device design and regulatory compliance. Was lead engineer on designing & successfully commercializing 3 medical devices. Supported by clinical and technical advisors with backgrounds in gastroenterology, otolaryngology, radiology, ultrasound physics, regulatory, finances and legal.

Customer Problem:

Patients do not tolerate the current invasive procedures, and Clinicians desire to improve their patients' standard of care while increasing profitability by avoiding referring cases out of office.

Product/Services:

SondeFlux, a non-invasive. Low-cost diagnostic device which uses ultrasound to detect reflux. Consists of an ambulatory recording box, disposable sensors and a software user interface.

Target Market:

Beach Head - Private practice Otolaryngologists, Primary - Adult and pediatric Gastroenterologists, Secondary – Neonatal intensive care units and geriatric care facilities.

Customers:

Influencer - Otolaryngologists and Gastroenterologists, Buyer – Office Manager and Purchasing Groups, End User – Patient.

Sales/Marketing Strategy:

Publish efficacy studies in Journal of Dysphagia, AAO-HNSF and Gastroenterology, while presenting at annual Ears Nose and Throat and Gastroenterology conferences. Direct sales to private practices, utilize distributors approved by hospital purchasing groups.

Business model:

In the US 6 Million people seek clinical care for reflux related symptoms. 800k Diagnostic tests are performed annually leading to a SOM of \$80 Million. Otolaryngologists refer 1.6 Million cases out of office equating to \$800 Million in lost revenue.

Competitors:

Given Imaging – Bravo pH system (Acquired by Medtronic) Sandhill Scientific – Impedance pH

Financials*	2022	2023	2024	2025
Grants	\$0	\$500	\$500	\$1,000
Sales	\$0	\$0	\$0	\$30
Expenditure	\$10	\$500	\$500	\$800
Net	\$-10	\$0	\$0	\$230

*In Thousands (000) in USD

Company Profile:

URL: www.reflodx.com Industry: Medical Devices Founded: 2015

Contact:

Name Rudy Wilcox Email rudy@reflodx.com Phone 801.885.3933

Financial Information:

Grant Funding: **\$1.63 M** Founders Investment: **\$55k** Monthly burn Rate: **\$30k** Pre Money valuation: **TBD**

Management:

Rudy Wilcox CEO

Clinical Advisors:

Dr. Daniel Jackson – Gl Dr. Marshall Smith – ENT Dr. JBK – SLP

Technical Advisors:

B. Mendenhall – financial J. Ziobro – regulatory Durham Jones & Pinegar – legal

Ask:

\$1 Million in Equity COO to get to next Level